Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy
Baofa Yu,1–3 Yuanfei Lu,1 Feng Gao,2 Peng Jing,2 Han Wei,1 Peicheng Zhang,2 Guoliang Liu,1 Ning Ru,2 Guanghui Cui,2 Xinhai Xu,1 Chenglin Sun,1 Changjiang Guan,2 Yebing Che,1 Yingli Wu,2 Zhenlu Ma,2 Qiang Fu,1 Jian Liu,2 Huan-You Wang4 1Jinan Baofa Cancer Hospital, Jinan, 2TaiMei Baofa Can...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e84454e4eb9643bd8df3206e2e796aa0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e84454e4eb9643bd8df3206e2e796aa0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e84454e4eb9643bd8df3206e2e796aa02021-12-02T03:41:12ZHapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy1179-2728https://doaj.org/article/e84454e4eb9643bd8df3206e2e796aa02015-01-01T00:00:00Zhttp://www.dovepress.com/hapten-enhanced-therapeutic-effect-in-advanced-stages-of-lung-cancer-b-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728 Baofa Yu,1–3 Yuanfei Lu,1 Feng Gao,2 Peng Jing,2 Han Wei,1 Peicheng Zhang,2 Guoliang Liu,1 Ning Ru,2 Guanghui Cui,2 Xinhai Xu,1 Chenglin Sun,1 Changjiang Guan,2 Yebing Che,1 Yingli Wu,2 Zhenlu Ma,2 Qiang Fu,1 Jian Liu,2 Huan-You Wang4 1Jinan Baofa Cancer Hospital, Jinan, 2TaiMei Baofa Cancer Hospital, Dongping, 3Beijing Baofa Cancer Hospital, Beijing, People’s Republic of China; 4Department of Pathology, University of California, San Diego, CA, USAAim: The objective of the study reported here was to evaluate the therapeutic effects of hapten-enhanced chemoimmunotherapy in the treatment of advanced lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy (UMIPIC) and to analyze the effect of this immune booster.Materials and methods: A total of 97 patients with advanced lung cancer were treated with UMIPIC or intratumoral chemotherapy (ITCT). UMIPIC was delivered intratumorally in combination with a proprietary therapeutic regimen composed of three components – an oxidant, a cytotoxic drug, and hapten. ITCT applied using the same procedures and regimen, only without hapten. All data from the two groups were reviewed and analyzed. A total of 55 patients were treated with UMIPIC and 42 with ITCT. Patient responses were assessed with computed tomography scan 4–6 weeks after treatment, and all of the patients were followed until their deaths.Results: Median overall survival was 11.23 months in the UMIPIC (test) group and 5.62 months in the ITCT (control) group (P<0.01). The 6-month and 1-year survival rates of the UMIPIC and ITCT groups were 76.36% versus 45.23% (P<0.01) and 45.45% versus 23.81% (P<0.05), respectively. Two cycles of UMIPIC treatment (n=19) conferred a significant survival benefit compared with two cycles of ITCT (n=29); significant benefits in survival time were also found with UMIPIC (n=20) compared with ITCT (n=13) when both were utilized without adjuvant treatment.Conclusion: The hapten-enhanced clinical effect of UMIPIC conferred a superior survival time in patients with advanced lung cancer compared with ITCT. The addition of the hapten in UMIPIC demonstrates a significant advantage in terms of prolonged survival time.Keywords: hapten-enhanced immunotherapy, intratumoral chemoimmunotherapy, lung cancer, ultra-minimum incision therapyYu BFLu YFGao FJing PHan WZhang PCLiu GLRu NCui GHXu XHSun CLGuan CJChe YBWu YLMa ZLFu QLiu JWang HYDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 1-11 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yu BF Lu YF Gao F Jing P Han W Zhang PC Liu GL Ru N Cui GH Xu XH Sun CL Guan CJ Che YB Wu YL Ma ZL Fu Q Liu J Wang HY Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy |
| description |
Baofa Yu,1–3 Yuanfei Lu,1 Feng Gao,2 Peng Jing,2 Han Wei,1 Peicheng Zhang,2 Guoliang Liu,1 Ning Ru,2 Guanghui Cui,2 Xinhai Xu,1 Chenglin Sun,1 Changjiang Guan,2 Yebing Che,1 Yingli Wu,2 Zhenlu Ma,2 Qiang Fu,1 Jian Liu,2 Huan-You Wang4 1Jinan Baofa Cancer Hospital, Jinan, 2TaiMei Baofa Cancer Hospital, Dongping, 3Beijing Baofa Cancer Hospital, Beijing, People’s Republic of China; 4Department of Pathology, University of California, San Diego, CA, USAAim: The objective of the study reported here was to evaluate the therapeutic effects of hapten-enhanced chemoimmunotherapy in the treatment of advanced lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy (UMIPIC) and to analyze the effect of this immune booster.Materials and methods: A total of 97 patients with advanced lung cancer were treated with UMIPIC or intratumoral chemotherapy (ITCT). UMIPIC was delivered intratumorally in combination with a proprietary therapeutic regimen composed of three components – an oxidant, a cytotoxic drug, and hapten. ITCT applied using the same procedures and regimen, only without hapten. All data from the two groups were reviewed and analyzed. A total of 55 patients were treated with UMIPIC and 42 with ITCT. Patient responses were assessed with computed tomography scan 4–6 weeks after treatment, and all of the patients were followed until their deaths.Results: Median overall survival was 11.23 months in the UMIPIC (test) group and 5.62 months in the ITCT (control) group (P<0.01). The 6-month and 1-year survival rates of the UMIPIC and ITCT groups were 76.36% versus 45.23% (P<0.01) and 45.45% versus 23.81% (P<0.05), respectively. Two cycles of UMIPIC treatment (n=19) conferred a significant survival benefit compared with two cycles of ITCT (n=29); significant benefits in survival time were also found with UMIPIC (n=20) compared with ITCT (n=13) when both were utilized without adjuvant treatment.Conclusion: The hapten-enhanced clinical effect of UMIPIC conferred a superior survival time in patients with advanced lung cancer compared with ITCT. The addition of the hapten in UMIPIC demonstrates a significant advantage in terms of prolonged survival time.Keywords: hapten-enhanced immunotherapy, intratumoral chemoimmunotherapy, lung cancer, ultra-minimum incision therapy |
| format |
article |
| author |
Yu BF Lu YF Gao F Jing P Han W Zhang PC Liu GL Ru N Cui GH Xu XH Sun CL Guan CJ Che YB Wu YL Ma ZL Fu Q Liu J Wang HY |
| author_facet |
Yu BF Lu YF Gao F Jing P Han W Zhang PC Liu GL Ru N Cui GH Xu XH Sun CL Guan CJ Che YB Wu YL Ma ZL Fu Q Liu J Wang HY |
| author_sort |
Yu BF |
| title |
Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy |
| title_short |
Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy |
| title_full |
Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy |
| title_fullStr |
Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy |
| title_full_unstemmed |
Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy |
| title_sort |
hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/e84454e4eb9643bd8df3206e2e796aa0 |
| work_keys_str_mv |
AT yubf haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT luyf haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT gaof haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT jingp haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT hanw haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT zhangpc haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT liugl haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT run haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT cuigh haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT xuxh haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT suncl haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT guancj haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT cheyb haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT wuyl haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT mazl haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT fuq haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT liuj haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy AT wanghy haptenenhancedtherapeuticeffectinadvancedstagesoflungcancerbyultraminimumincisionpersonalizedintratumoralchemoimmunotherapytherapy |
| _version_ |
1718401705229418496 |